Mucosal safety of PHI-443 and stampidine as a combination microbicide to prevent genital transmission of HIV-1

Fertility and Sterility

Volumn 88, Issue 4 SUPPL., 2007, Pages 1197-1206

  D'Cruz, Osmond J ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

chemokines; cytokines; HIV AIDS; inflammation; microbicide; vagina

Indexed keywords

CHEMOKINE; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MICROBICIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; N' [2 (2 THIOPHENYLETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; PHI 443; RANTES; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAMPIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; COCULTURE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GEL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LANGERHANS CELL; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCORING SYSTEM; VAGINA EPITHELIUM; VAGINA MUCOSA; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MUCOUS MEMBRANE; PYRIDINES; RABBITS; STAVUDINE; THIOUREA; THYMIDINE MONOPHOSPHATE; VAGINA;

EID: 34948882831     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.01.131     Document Type: Article

References (59)

1. D'Cruz O.J., and Uckun F.M. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 10 (2004) 315-336
2. UNAIDS. Report on the Global HIV/AIDS Epidemic: May 2006. http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp (September 14, 2006 date last accessed).
3. National Institute of Allergy and Infectious Diseases Fact Sheet: May 2006. HIV Infection in Women. http://www.niaid.nih.gov/factsheets/womenhiv.htm (September 14, 2006 date last accessed).
4. European Study Group on Heterosexual Transmission of HIV. Comparison of female-to-male and male-to-female transmission of HIV in 563 stable couples. BMJ 304 (1992) 809-813
5. D'Cruz O.J., and Uckun F.M. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 57 (2006) 411-423
6. D'Cruz O.J., and Uckun F.M. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. Curr HIV Res 4 (2006) 329-345
7. D'Cruz O.J., Waurzyniak B., and Uckun F.M. Antiretroviral spermicide WHI-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother 48 (2004) 1082-1088
8. Uckun F.M., and D'Cruz O.J. Prophylactic contraceptives for HIV/AIDS. Human Reprod Update 5 (1999) 506-514
9. Kozal M.J., Amico K.R., Chiarella J., Schreibman T., Cornman D., Fisher W., et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 18 (2004) 2185-2189
10. Madan R.P., Keller M.J., and Herold B.C. Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr Opin Infect Dis 19 (2006) 49-54
11. Neurath A.R., Strick N., and Li Y.Y. Role of seminal plasma in the anti-HIV activity of candidate microbicides. BMC Infect Dis 6 (2006) 150
12. D'Cruz O.J., Samuel P., and Uckun F.M. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide. Biol Reprod 71 (2004) 2037-2047
13. D'Cruz O.J., and Uckun F.M. Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertil Steril 81 Suppl 1 (2004) 831-841
14. D'Cruz O.J., and Uckun F.M. Stampidine: a selective oculo-genital microbicide. J Antimicrob Chemother 56 (2005) 10-19
15. Uckun F.M., Venkatachalam T.K., and Qazi S. Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittel-Forschung/Drug Res 56 (2006) 193-203
16. Uckun F.M., Pendergrass S., Venkatachalam T., Qazi S., and Richman D. Stampidine is a potent inhibitor of zidovudine and NRTI-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 46 (2002) 3613-3616
17. D'Cruz O.J., and Uckun F.M. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Enzyme Inhib Med Chem 21 (2006) 329-350
18. Uckun F.M., Pendergrass S., Qazi S., Samuel P., and Venkatachalam T. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates. Arzneimittel-Forschung/Drug Res 54 (2004) 69-77
19. Uckun F.M., Qazi S., Pendergrass S., Lisowiski E., Waurzyniak B., Chen C.L., et al. In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5′-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 46 (2002) 3428-3436
20. Uckun F.M., Chen C.L., Samuel P., Pendergrass S., Venkatachalam T.K., Waurzyniak B., et al. In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 47 (2003) 1233-1240
21. Uckun F.M., Venkatachalam T.K., and Erbeck D. In vivo pharmacokinetics, metabolism, toxicity, and anti-HIV activity of N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)]thiourea (PHI-443), a potent NNRTI compound. Arzneimittel-Forschung/Drug Res (2007) in press
22. Lore K., and Larsson M. The role of dendritic cells in the pathogenesis of HIV-1 infection. APMIS 111 (2003) 776-788
23. Kawamura T., Gulden F.O., Sugaya M., McNamara D.T., Borris D.L., Lederman M.M., et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 100 (2003) 8401-8406
24. Tchou I., Misery L., Sabido O., Dezutter-Dambuyant C., Bourlet T., Moja P., et al. Functional HIV CXCR4 coreceptor on human epithelial Langerhans cells and infection by HIV strain X4. J Leukoc Biol 70 (2001) 313-321
25. Charbonnier A.S., Kohrgruber N., Kriehuber E., Stingl G., Rot A., and Maurer D. Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med 190 (1999) 1755-1768
26. Cremel M., Berlier W., Hamzeh H., Cognasse F., Lawrence P., Genin C., et al. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 78 (2005) 158-166
27. Dieu-Nosjean M.C., Vicari A., Lebecque S., and Caux C. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 66 (1999) 252-262
28. Wilflingseder D., Banki Z., Dierich M.P., and Stoiber H. Mechanisms promoting dendritic cell-mediated transmission of HIV. Mol Immunol 42 (2005) 229-237
29. D'Cruz O.J., Samuel P., and Uckun F.M. Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. AAPS PharmSciTech 6 (2005) E56-E64. http://www.aapspharmscitech.org/prepub/prepub.asp September 14, 2006
30. Eckstein P., Jackson M.C., Millman N., and Sobrero A.J. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 20 (1969) 85-93
31. Rosdy M., Bernard B.A., Schmidt R., and Darmon M. Incomplete epidermal differentiation of A431 epidermoid carcinoma cells. In Vitro Cell Dev Biol 22 (1986) 295-300
32. Knuechel R., Keng P., Hofstaedter F., Langmuir V., Sutherland R.M., and Penney D.P. Differentiation patterns in two- and three-dimensional culture systems of human squamous carcinoma cell lines. Am J Pathol 137 (1990) 725-736
33. Steele C., and Fidel Jr. P.L. Cytokine and chemokine production by human oral and vaginal epithelial cells in response to Candida albicans. Infect Immunol 70 (2002) 577-583
34. Moody M.D., Van Arsdell S.W., Murphy K.P., Orencole S.F., and Burns C. Array-based ELISAs for high-throughput analysis of human cytokines. Biotechniques 31 (2001) 186-190
35. D'Cruz O.J., Dong Y., and Uckun F.M. Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer. Anticancer Drugs 11 (2000) 849-858
36. D'Cruz O.J., Erbeck D., and Uckun F.M. A study of the potential of the pig as a model for the vaginal irritancy of benzalkonium chloride in comparison to the nonirritant microbicide PHI-443 and the spermicide vanadocene dithiocarbanate. Toxicol Pathol 33 (2005) 465-476
37. Kawamura T., Cohen S.S., Borris D.L., Aquilino E.A., Glushakova S., Margolis L.B., et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 192 (2000) 1491-1500
38. Aebischer F., and McDougall J.K. Organotypic raft cultures for the in vitro evaluation of vaginal microbicidal agents. Microbicides have epithelium-specific effects when repeatedly added onto organotypic human keratinocyte cultures. Sex Transm Dis 24 (1997) 69-76
39. Fichorova R.N., Tucker L.D., and Anderson D.J. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184 (2001) 418-428
40. Heinonen P.K., Teisala K., Punnonen R., Miettinen A., Lehtinen M., and Paavonen J. Anatomic sites of upper genital tract infection. Obstet Gynecol 66 (1985) 384-390
41. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6 (1997) 315-325
42. Quayle A.J. The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J Reprod Immunol 57 (2002) 61-79
43. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996) 667-673
44. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., and Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270 (1995) 1811-1815
45. Iversen A.K., Fugger L., Eugen-Olsen J., Balslev U., Jensen T., Wahl S., et al. Cervical human immunodeficiency virus type 1 shedding is associated with genital beta-chemokine secretion. J Infect Dis 178 (1998) 1334-1342
46. Sturm-Ramirez K., Gaye-Diallo A., Eisen G., Mboup S., and Kanki P.J. High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J Infect Dis 182 (2000) 467-473
47. Narimatsu R., Wolday D., and Patterson B.K. IL-8 increases transmission of HIV type 1 in cervical explant tissue. AIDS Res Hum Retroviruses 21 (2005) 228-233
48. Kayisli U.A., Mahutte N.G., and Arici A. Uterine chemokines in reproductive physiology and pathology. Am J Reprod Immunol 47 (2002) 213-221
49. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
50. Mayer K.H., and Anderson D.J. Heterosexual HIV transmission. Infect Agents Dis 4 (1995) 273-284
51. Wright Jr. T.C., Subbarao S., Ellerbrock T.V., Lennox J.L., Evans-Strickfaden T., Smith D.G., et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 184 (2001) 279-285
52. Prakash M., Patterson S., and Kapembwa M.S. Hormonal upregulation of CCR5 expression on T lymphocytes as a possible mechanism for increased HIV-1 risk. J Acquir Immune Defic Syndr 38 Suppl 1 (2005) S14-S16
53. Sivard P., Berlier W., Picard B., Sabido O., Genin C., and Misery L. HIV-1 infection of Langerhans cells in a reconstructed vaginal mucosa. J Infect Dis 190 (2004) 227-235
54. Chen C.L., Yu G., Venkatachalam T.K., and Uckun F.M. Metabolism of stavudine-5′-[p-bromophenyl methoxyalaninyl phosphate], stampidine, in mice, dogs, and cats. Drug Metab Dispos 30 (2002) 1523-1531
55. Uckun F.M., Chen C.L., Lisowski E., Mitcheltree G., Venkatachalam T.K., Erbeck D., et al. Toxicity and pharmacokinetics of stampidine in mice and rats. Arzneimittel-Forschung/Drug Res 53 (2003) 357-367
56. D'Cruz O.J., Samuel P., Waurzyniak B., and Uckun F.M. In vivo evaluation of a gel formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Am J Drug Deliv 1 (2003) 275-285
57. D'Cruz O.J., Erbeck D., and Uckun F.M. Developmental safety profile of the anti-HIV agent stampidine in rabbits. Arzneimittel-Forschung/Drug Res 56 (2006) 159-166
58. Dumez D., Venkatachalam T., and Uckun F.M. Large-scale synthesis of GMP grade N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea [PHI-443], a new anti-HIV drug candidate. Arzneimittel-Forschung/Drug Res (2007) in press
59. DuMez D., Venkatachalam T.K., and Uckun F.M. Large-scale synthesis and formulation of GMP-grade stampidine, a new anti-HIV agent. Arzneimittel-Forschung/Drug Res 56 (2006) 136-151